J&J added that Consumer Health worldwide adjusted operational sales grew +11.3% mainly due to over-the-counter (OTC) products. J&J's Consumer Health segment sales in Q1 increased +7.4% Y/Y to $3.85B. Global sales of Remicade fell -26.5% Y/Y to $487M Imbruvica sales declined -20.3% Y/Y to $827M, while Zytiga's worldwide revenue slumped -54.5% Y/Y to $245M. J&J, noted that the growth in the Pharma division was partially offset by declines in sales of autoimmune diseases drug Remicade, blood cancer drug Imbruvica, and prostate cancer therapy Zytiga. Meanwhile, worldwide sales of Xarelto grew +13.7 to $578M.ĬOVID-19 Vaccine sales were only internationally and not in the U.S. Global sales of Carvykti in Q1 were $72M. Worldwide Erleada sales increased +35.6% to $542M. Global sales of Stelara, which treats immune-mediated inflammatory diseases, rose +6.8% Y/Y to ~$2.44B. Worldwide sales of Darzalex, developed with Genmab ( GMAB), grew +22 Y/Y to ~$2.26B. Revenue was also boosted by sales of COVID-19 Vaccine (). J&J said worldwide adjusted operational sales grew 7.2%, driven by blood cancer drug Darzalex, Stelara, prostate cancer therapy Erleada, CAR-T immunotherapy Carvykti and anticoagulant drug Xarelto. Sales from the Pharmaceutical division in Q1 increased +4.2% Y/Y to $13.41B. "Our first quarter results demonstrate strong performance across all three segments of our business and reflect the dedication of Johnson & Johnson colleagues around the world," said Chairman and CEO Joaquin Duato. Both top and bottom line beating analysts expectations. However, GAAP EPS was -$0.03, declining -101.6% Y/Y due to a special one-time charge. Q4 adjusted EPS grew marginally +0.4% Y/Y to $2.68. Johnson & Johnson ( NYSE: JNJ) is trading in the green premarket on Tuesday after Q1 results beat estimates and the company raised its FY23 outlook.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |